Episurf Medical receives market approval in Israel and signs distribution agreement for the Israeli market
Episurf Medical (NASDAQ: EPIS B) today announces that the Israeli Ministry of Health has approved Episurf Medical’s Episealer® knee products for the Israeli market. The approval follows a review process. Episurf Medical further announces that the company has entered into a distribution agreement for the Israeli market with AMI Technologies Ltd., a leading distributor of medical devices in Israel.
“We are very happy to continue executing on our global strategy by opening up our first distribution market. This is an important step for Episurf Medical” says Pål Ryfors, CEO Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on 18 January 2018.
Tags: